Healthcare: 19 A-Grades, Insurance Still Failing

The Sector That Works (Mostly)

Healthcare just posted 19 A-grades out of 29 companies. That's a 66% success rate, higher than tech, higher than industrials, higher than almost everything except real estate. The median FCF margin sits at 16.1%. Twenty companies show improving trends. On paper, this looks like one of the market's healthiest sectors.

But those six F-grades tell a different story. They're all in the same business: health insurance. And they're not failing quietly.

Pharma Still Prints Cash

Gilead leads the sector at 29.1% FCF margin with an improving trend. AbbVie sits right behind at 27.6%, also improving. Bristol-Myers posts 25.5%, though that trend is declining. Zoetis and IDEXX round out the top five, both above 22%.

These aren't growth stories. These are mature pharmaceutical and animal health companies converting revenue into cash at rates that would make tech investors jealous. The sector threshold for an A-grade is 15% FCF margin. Every one of these top performers clears it by at least seven percentage points.

Vertex, Amgen, Danaher, DexCom, Regeneron. All A-grades. All above 19% margins. Johnson & Johnson, Merck, Biogen, Intuitive Surgical, Stryker. Same story. The device makers and pharma giants have figured out how to generate consistent, predictable cash flow regardless of what the broader market does.

Even the B-grades look fine. Medtronic at 13.7%, Pfizer at 13.2%, Align at 7.6%. These companies aren't exciting, but they're not broken. Thermo Fisher sits at 13.4% with an A-grade and an improving trend. The fundamentals work.

The Insurance Problem

Then you hit the insurers.

UnitedHealth, the largest health insurer in the country, posts a 3.4% FCF margin. Cigna manages 3.1%. CVS scrapes together 1.8% and is declining. Elevance hits 1.5%. Humana barely registers at 0.1%.

Four of them show improving trends, which sounds encouraging until you realize they're improving from terrible to slightly less terrible. CVS is declining into an even worse position. These are massive companies with enormous revenues. They're not startups burning through venture capital. They're supposed to be stable, mature businesses. Instead, they convert almost nothing to free cash flow.

The sector average debt-to-FCF ratio is 7.6x, which looks manageable. But that number gets pulled down by the pharma companies with pristine balance sheets. The insurers carry significantly more leverage against far weaker cash generation. When your FCF margin is under 2%, even moderate debt becomes a problem.

Moderna's Special Disaster

Moderna deserves its own mention. A -133.1% FCF margin means the company is burning cash at a rate that exceeds its entire revenue base. The trend shows as improving, but improving from catastrophic to merely disastrous still leaves you in F territory.

This is what happens when a one-product pandemic windfall meets normal market conditions. The company scaled up for COVID vaccine demand that no longer exists. Now it's stuck with infrastructure costs and R&D spending that its current revenue can't support. The cash burn is extraordinary even by biotech standards.

What the Trends Say

Twenty companies improving, three stable, six declining. That's an encouraging split. Pharma is benefiting from stable pricing power and patent portfolios that keep generics at bay. Device makers are riding procedure volume recovery and hospital capital spending. Even the struggling names like Bristol-Myers and Zoetis show strong absolute margins despite declining trends.

The declining trends mostly show up in companies that are still highly profitable. DexCom at 19.7%, Regeneron at 19.3%, Boston Scientific at 15.5%. These aren't crises. They're high-performing companies giving back some margin, often due to R&D investments or competitive pressure in specific product lines.

Lilly stands out as an exception. An 8.2% margin with a C-grade and improving trend. The company is pouring money into manufacturing capacity for its obesity drugs. That capital intensity hurts near-term FCF even as revenue growth accelerates. It's a temporary problem for a fundamentally strong business, but the grade reflects current reality, not future potential.

The Real Question

Why can pharma and devices print cash while insurance destroys it?

Part of it is business model. Drug makers own patents and charge high margins on molecules that took billions to develop. Once the R&D is sunk, incremental production is cheap. Device makers operate similarly: high upfront costs, strong margins on sales.

Insurance is different. It's a volume business with tight regulatory margins and constant medical cost inflation. Insurers collect premiums and pay claims. When medical costs rise faster than premium increases, margins compress. When utilization spikes, cash flow craters. The business has no pricing power and limited ability to control its largest expense.

The insurers also carry operational complexity that pharma avoids. Claims processing, provider networks, regulatory compliance, pharmacy benefit management. All of it requires infrastructure that costs money but doesn't generate margin.

What It Means

Healthcare works if you stick to pharma and devices. Nineteen A-grades concentrated in companies that own intellectual property and control their cost structures. Strong trends, improving fundamentals, margins that support healthy balance sheets.

The insurance side is a different sector wearing a healthcare label. Low margins, weak cash generation, structural challenges that aren't getting better. Four out of five show improving trends, but they're improving within a fundamentally broken model.

The sector split is clear. Own the cash generators. Avoid the premium collectors.